Cancer progression is driven in part by genomic alterations 1 . The genomic characterization
of cancers has shown interpatient heterogeneity regarding driver alterations 2 , leading to …

Circulating tumor cells (CTCs) are rare tumor cells and have been investigated as diagnostic,
prognostic and predictive biomarkers in many types of cancer. Although CTCs are not …

The impact of single-agent antibodies against programmed death-ligand 1 (PD-L1) as
maintenance therapy is unknown in patients with metastatic breast cancer. The SAFIR02-BREAST …

A significant proportion of patients with oestrogen receptor (ER) positive breast cancers (BC)
develop resistance to endocrine treatments (ET) and relapse with metastatic disease. Here …

Topoisomerase I (TOP1) inhibitors trap TOP1 cleavage complexes resulting in DNA double-strand
breaks (DSBs) during replication, which are repaired by homologous recombination (…

Purpose Few studies evaluated the prognostic value of the presence of lymphovascular
invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC). Methods The …

Purpose: Triple-negative breast cancer (TNBC) patients with residual disease after neoadjuvant
chemotherapy have a poor outcome. We developed patient-derived xenografts (PDX) …

Triple‐negative breast cancer (TNBC) represents 10% of all breast cancers and is a very
heterogeneous disease. Globally, women with TNBC have a poor prognosis, and the …

Few studies have reported reproductive outcomes after breast cancer chemotherapy. The
relationship between anti-Müllerian hormone (AMH) concentrations and the occurrence of …

Aims High‐grade metaplastic breast carcinoma (HG‐MBC) is a rare subtype of invasive
breast carcinoma, mostly triple‐negative. Metaplastic carcinomas are less responsive to …